NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
28 October 2025
| Name: | VECTUS BIOSYSTEMS LIMITED (VBS) |
| ISIN: | AU000000VBS9 |
| Date of Listing: | 23 February 2016 |
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 117 526 137ABN: 54 117 526 137
Registration Date: 12 December 2005
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Computershare Brisbane
Level 1, 200 Mary Street Brisbane QLD 4000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 7 3229 9860
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Vectus Biosystems Limited will be lifted immediately following the release by VBS of an announcement regarding a material transaction in relation to a compound in the Vectus drug library. | 17/10/2025 |
The company has finalized a binding Term Sheet with XORTX Therapeutics for the sale of its VB4-P5 Renal Small Molecule Compound, targeting renal fibrosis. The deal, valued at US$3 million, includes shares and pre-funded warrants in XORTX. Vectus aims to retain an interest in VB4-P5's development while focusing on its cardiovascular candidate, VB0004, and ensuring no further financial contributions are needed for VB4-P5's commercialization. Closing is expected within 90 days. | 17/10/2025 |
The company's securities suspended pending announcement, as requested by VBS. | 17/10/2025 |
listed entity carried for record purposes only | 23/02/2016 |
The suspension of trading in the securities of Vectus Biosystems Limited will be lifted immediately following the release by VBS of an announcement regarding a material transaction in relation to a compound in the Vectus drug library. | 17/10/2025 |
The company has finalized a binding Term Sheet with XORTX Therapeutics for the sale of its VB4-P5 Renal Small Molecule Compound, targeting renal fibrosis. The deal, valued at US$3 million, includes shares and pre-funded warrants in XORTX. Vectus aims to retain an interest in VB4-P5's development while focusing on its cardiovascular candidate, VB0004, and ensuring no further financial contributions are needed for VB4-P5's commercialization. Closing is expected within 90 days. | 17/10/2025 |
The company's securities suspended pending announcement, as requested by VBS. | 17/10/2025 |
listed entity carried for record purposes only | 23/02/2016 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 27/05/2016 | Susan Pond | 21,500 | $1.380 | $29,670 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Maurie Stang | Non Exec Chairman, Deputy Chairman | 23/02/2016 |
| Ronald Shnier | Non Exec Director | 23/02/2016 |
| Susan Pond | Non Exec Director | 04/05/2016 |
| Linda Walters | Non Exec Director | 20/12/2024 |
| Robert Waring | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Karen Duggan | Executive Director, CEO | 23/02/2016 | 20/05/2024 |
| Peter Bush | Non Exec Director | 23/02/2016 | 25/11/2022 |
| Graham Macdonald | Non Exec Chairman | 23/02/2016 | 31/08/2018 |
| Bernard Stang | Non Exec Director | 12/12/2005 | 28/10/2016 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
